Literature DB >> 7697540

Alterations in levels of CD28-/CD8+ suppressor cell precursor and CD45RO+/CD4+ memory T lymphocytes in the peripheral blood of multiple sclerosis patients.

B Crucian1, P Dunne, H Friedman, R Ragsdale, S Pross, R Widen.   

Abstract

A comprehensive peripheral blood immunophenotype analysis of 16 multiple sclerosis (MS) patients was performed by three-color flow cytometric analysis, and the results were compared with those for age-matched healthy controls. The cell subsets quantified included T cells (CD3+), B cells (CD19+), NK cells (CD56+), CD4+ and CD8+ T cells, cytotoxic (CD28+) and suppressor precursor (CD28-) CD8+ T cells, CD45RA+ and CD45RO+ T cells (CD4+ and CD8+), and CD5+ T and B cells. Analysis of MS patients' peripheral blood revealed essentially normal levels of total T, B, and NK cells. In agreement with results obtained by other investigators, it was found that MS patients had an increased CD4/CD8 ratio, primarily due to a decrease in CD8+ T cells. MS patients were found to have a significantly decreased level of suppressor precursor (CD28-) CD8+ T cells compared with that of controls but to have normal levels of cytotoxic (CD28+) CD8+ T cells. These data indicate that MS patients do not have a general decrease in CD8+ T cells but that they have a specific decrease in the suppressor precursor subset only and normal levels of cytotoxic CD8+ T cells. MS patients also had a significant increase in memory (CD45RO+) CD4+ T cells and displayed a trend towards a decrease in naive (CD45RA+) T cells in the peripheral blood.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7697540      PMCID: PMC170139          DOI: 10.1128/cdli.2.2.249-252.1995

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  28 in total

1.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

2.  Correlation of immunological studies and disease progression in chronic progressive multiple sclerosis.

Authors:  J L Trotter; D B Clifford; J E McInnis; R C Griffeth; K A Bruns; M S Perlmutter; C B Anderson; K G Collins; G Banks; B C Hicks
Journal:  Ann Neurol       Date:  1989-02       Impact factor: 10.422

3.  Loss of functional suppression is linked to decreases in circulating suppressor inducer (CD4+ 2H4+) T cells in multiple sclerosis.

Authors:  M Chofflon; H L Weiner; C Morimoto; D A Hafler
Journal:  Ann Neurol       Date:  1988-08       Impact factor: 10.422

4.  Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions.

Authors:  S L Hauser; A K Bhan; F Gilles; M Kemp; C Kerr; H L Weiner
Journal:  Ann Neurol       Date:  1986-06       Impact factor: 10.422

5.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

6.  Loss of suppressor T cells in active multiple sclerosis. Analysis with monoclonal antibodies.

Authors:  E L Reinherz; H L Weiner; S L Hauser; J A Cohen; J A Distaso; S F Schlossman
Journal:  N Engl J Med       Date:  1980-07-17       Impact factor: 91.245

7.  T lymphocyte populations in multiple sclerosis.

Authors:  U Rodeck; E Kuwert; H W Scharafinski; H J Lehmann
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1985

8.  A defect of immunoregulatory T cell subsets in systemic lupus erythematosus patients demonstrated with anti-2H4 antibody.

Authors:  C Morimoto; A D Steinberg; N L Letvin; M Hagan; T Takeuchi; J Daley; H Levine; S F Schlossman
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

9.  Fluctuations of CD4+ T-cell subsets in remitting-relapsing multiple sclerosis.

Authors:  L M Rose; A H Ginsberg; T L Rothstein; J A Ledbetter; E A Clark
Journal:  Ann Neurol       Date:  1988-08       Impact factor: 10.422

10.  Selective loss of the suppressor-inducer T-cell subset in progressive multiple sclerosis. Analysis with anti-2H4 monoclonal antibody.

Authors:  C Morimoto; D A Hafler; H L Weiner; N L Letvin; M Hagan; J Daley; S F Schlossman
Journal:  N Engl J Med       Date:  1987-01-08       Impact factor: 91.245

View more
  24 in total

1.  Expression of CCR2, CCR5, and CXCR3 by CD4+ T cells is stable during a 2-year longitudinal study but varies widely between individuals.

Authors:  Pia Kivisäkk; Corinna Trebst; Jar-Chi Lee; Barbara H Tucky; Richard A Rudick; James J Campbell; Richard M Ransohoff
Journal:  J Neurovirol       Date:  2003-06       Impact factor: 2.643

2.  Active Crohn's disease patients show a distinctive expansion of circulating memory CD4+CD45RO+CD28null T cells.

Authors:  Jaime García de Tena; Luis Manzano; Juan Carlos Leal; Esther San Antonio; Verónica Sualdea; Melchor Alvarez-Mon
Journal:  J Clin Immunol       Date:  2004-03       Impact factor: 8.317

3.  Differences in systemic and central nervous system cellular immunity relevant to relapsing-remitting multiple sclerosis.

Authors:  Makoto Matsui; Shin-ichi Araya; Hui-Yun Wang; Kouji Matsushima; Takahiko Saida
Journal:  J Neurol       Date:  2005-03-21       Impact factor: 4.849

Review 4.  Inflammation and adaptive immunity in Parkinson's disease.

Authors:  R Lee Mosley; Jessica A Hutter-Saunders; David K Stone; Howard E Gendelman
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 5.  CD8(+) Tregs in autoimmunity: learning "self"-control from experience.

Authors:  Sue Tsai; Xavier Clemente-Casares; Pere Santamaria
Journal:  Cell Mol Life Sci       Date:  2011-06-14       Impact factor: 9.261

Review 6.  Immune regulation of multiple sclerosis by CD8+ T cells.

Authors:  Sushmita Sinha; Farah R Itani; Nitin J Karandikar
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

7.  Hematological effects of intermittent 2-hour infusions of cladribine in multiple sclerosis patients: a comparison of 2 dosage patterns.

Authors:  P Grieb; J Kamienowski; M Janisz; P Kuśnierczyk; J Kawiak; G Hoser; S J Chrapusta
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

8.  Primary defect in CD8+ lymphocytes in the antibody deficiency disease (common variable immunodeficiency): abnormalities in intracellular production of interferon-gamma (IFN-gamma) in CD28+ ('cytotoxic') and CD28- ('suppressor') CD8+ subsets.

Authors:  M E North; A D Webster; J Farrant
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

9.  Alterations in peripheral blood mononuclear cell cytokine production in response to phytohemagglutinin in multiple sclerosis patients.

Authors:  B Crucian; P Dunne; H Friedman; R Ragsdale; S Pross; R Widen
Journal:  Clin Diagn Lab Immunol       Date:  1995-11

10.  CD28⁻ CD8⁺ T cells are significantly reduced and correlate with disease duration in juveniles with type 1 diabetes.

Authors:  Danielle N Yarde; Kristina Lorenzo-Arteaga; Kevin P Corley; Monina Cabrera; Nora E Sarvetnick
Journal:  Hum Immunol       Date:  2014-09-19       Impact factor: 2.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.